Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Natalie Reizine

Medical Oncology Chicago, IL Medical Doctor

NPI 1194106724 CMS profile 1332160

5841 S Maryland Ave # Mc3051, Chicago, IL 60637

Open in the dashboard

General payments

$65,835

117 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$181,944 paid to institutions, not to them · program years 2021–2025

Through program year 2025, Natalie Reizine of Chicago, IL is reported in the CMS Open Payments database as having received $65,835 across 117 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $181,944 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 85th percentile of Medical Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,576 12
2024 General $34,873 48
2023 General $24,940 41
2022 General $3,171 12
2020 General $114 1
2019 General $162 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Natalie Reizine
  • Medical Oncology median
  • Middle half of Medical Oncology
  • National median

In program year 2025, general payments to Natalie Reizine were reported at $2,576. Among 3,316 Medical Oncology profiles paid that year, the median was $1,128 and the middle half received between $147 and $5,675.

Show as a table
Year Natalie Reizine Medical Oncology median Middle half National median
2019 $162 $968 $140–$6,658 $163
2020 $114 $747 $102–$5,891 $114
2021 $0 $430 $50–$4,098 $132
2022 $3,171 $812 $127–$4,907 $149
2023 $24,940 $957 $144–$5,248 $160
2024 $34,873 $1,042 $149–$5,650 $164
2025 $2,576 $1,128 $147–$5,675 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $26,848 35 payments
  2. EMD Serono, Inc. $11,829 16 payments
  3. Merck Sharp & Dohme Corporation $9,829 13 payments
  4. Janssen Biotech, Inc. $9,145 7 payments
  5. Janssen Scientific Affairs, LLC $2,121 8 payments
  6. Exelixis Inc. $2,103 8 payments
  7. Aveo Pharmaceuticals, Inc. $1,755 5 payments
  8. Genzyme Corporation $1,383 1 payment
  9. Lilly USA, LLC $186 4 payments
  10. Novartis Pharmaceuticals Corporation $171 6 payments
  11. Other $465 14 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $52,385 26 payments
  2. Consulting Fee $5,308 5 payments
  3. Food and Beverage $4,318 68 payments
  4. Travel and Lodging $3,586 14 payments
  5. Education $219 3 payments
  6. Entertainment $19 1 payment
Products named General payments · program years 2019–2025
  1. LYNPARZA Oncology $26,828 34 payments
  2. ERLEADA $10,449 14 payments
  3. Bavencio $9,706 11 payments
  4. AKEEGA $9,383 10 payments
  5. KEYTRUDA $5,762 8 payments
  6. LYNPARZA Oncology $3,989 6 payments
  7. CABOMETYX Oncology $1,776 5 payments
  8. FOTIVDA $1,755 5 payments
  9. JEVTANA $1,383 1 payment
  10. CABOMETYX Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) $327 3 payments
  11. Other $1,319 36 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 8 drugs

Part D claims

428

Median for Medical Oncology: 414

Drug cost

$1,267,510

Median for Medical Oncology: $849,427

Branded share of claims

28.3%

Median for Medical Oncology: 28.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Erleada Apalutamide Brand 52 $740,598
Nubeqa Darolutamide Brand 35 $398,763
Abiraterone Acetate Generic 141 $120,478
Eliquis Apixaban Brand 13 $6,893
Prednisone Generic 136 $373
Loperamide Loperamide Hcl Brand 21 $341
Tamsulosin Hcl Generic 16 $49
Amlodipine Besylate Generic 14 $15

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,431 Part D prescribers listed as Medical Oncology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 12 billing codes

Paid by Medicare

$19,127

Medicare's payments for the services billed

Medicare patients

59

Average age 71

Services billed

218

16 women, 43 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Cancer 75%
Diabetes 46%
Chronic kidney disease 42%
Arthritis 36%
Heart failure 27%
Ischemic heart disease 25%
Atrial fibrillation 22%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 15 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
LYNPARZA
  • AstraZeneca Pharmaceuticals LP $19,816
$19,816 — —
ERLEADA
  • Janssen Biotech, Inc. $4,572
  • Janssen Scientific Affairs, LLC $70
$4,643 52 —
AKEEGA
  • Janssen Biotech, Inc. $4,572
  • Janssen Scientific Affairs, LLC $34
$4,606 — —
KEYTRUDA
  • Merck Sharp & Dohme Corporation $3,309
$3,309 — —
FOTIVDA
  • Aveo Pharmaceuticals, Inc. $1,210
$1,210 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 15 in the dashboard with a free account

Records

117 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Medical Oncology in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record